The
price of Chidamide varies by region, medical insurance policies and purchase
channels; for specific pricing, please consult local hospitals or licensed
pharmacies. This is a prescription drug and must be used under the guidance of a
physician for the treatment of specific types of peripheral T-cell lymphoma and
breast cancer. Patients shall not purchase or adjust the dosage of this drug on
their own.
Indications and Administration
1. Indications
Relapsed or refractory peripheral T-cell lymphoma (PTCL): applicable to patients who have received at least one course of systemic chemotherapy.
Hormone receptor-positive, HER2-negative breast cancer: used in combination with aromatase inhibitors for postmenopausal patients with locally advanced or metastatic breast cancer that has relapsed or progressed after endocrine therapy.
2. Recommended Dosage
For adult patients, take 30 mg (6 tablets) orally twice a week, at an interval of at least 3 days between the two doses, and administer after meals.
When used in combination with Exemestane, Exemestane shall be administered at a dose of 25 mg once daily.
Precautions
1. Hematological Monitoring
A complete blood count (CBC) must be performed before treatment to ensure that the levels of neutrophils, platelets and hemoglobin meet the required standards. CBC rechecks are required weekly during medication. In case of grade 3 or higher hematological adverse reactions (e.g., thrombocytopenia, neutropenia), the medication must be temporarily discontinued and symptomatic treatment given; dose adjustment may be needed after the recovery of relevant indicators.
2. Hepatic, Renal and Electrolyte Monitoring
Monitor hepatic and renal function on a regular basis; use with caution in patients with moderate to severe hepatic or renal impairment.
Monitor the levels of electrolytes such as serum potassium and serum calcium, and intervene in case of abnormalities.
3. Cardiac Safety
Monitor electrocardiogram (ECG) and electrolytes regularly during medication, and be alert to the risks of QTc interval prolongation or pericardial effusion. Use with caution in patients with a history of heart disease.
Special Populations
Pregnant and lactating women
Contraindicated. Effective contraception is required during treatment and for 3 months after drug discontinuation.
Pediatric patients
No safety data are available for patients under 18 years of age, and use is not recommended.
Geriatric patients
Dosage adjustment shall be made based on individual conditions, and adverse reactions shall be closely monitored.
Medical Supervision Instructions
Chidamide must be used in strict accordance with the physician's instructions; patients shall not discontinue or adjust the dosage at will. If symptoms such as fever, infection or bleeding occur during medication, immediate medical attention should be sought. There are individual differences in patients' tolerance and response to the drug, and the treatment plan shall be formulated on an individualized basis.
